Headlines about Quidel (NASDAQ:QDEL) have trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Quidel earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.7835638449879 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:
Quidel (NASDAQ QDEL) traded down $0.14 on Thursday, hitting $45.64. 549,703 shares of the stock traded hands, compared to its average volume of 343,882. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68. Quidel has a 1 year low of $18.25 and a 1 year high of $49.47. The stock has a market capitalization of $1,590.37, a PE ratio of -304.25, a price-to-earnings-growth ratio of 1.51 and a beta of 1.15.
Quidel (NASDAQ:QDEL) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.21). Quidel had a negative net margin of 2.33% and a negative return on equity of 2.36%. The company had revenue of $50.89 million for the quarter, compared to analysts’ expectations of $50.47 million. During the same period in the previous year, the firm earned $0.10 earnings per share. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. equities analysts predict that Quidel will post -0.23 earnings per share for the current year.
Several research firms recently commented on QDEL. Piper Jaffray Companies reissued a “buy” rating and set a $60.00 price objective on shares of Quidel in a research note on Wednesday, January 24th. BidaskClub lowered shares of Quidel from a “buy” rating to a “hold” rating in a research note on Wednesday. Barclays lifted their target price on shares of Quidel from $50.00 to $60.00 and gave the stock an “overweight” rating in a report on Monday, January 22nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $48.00 target price on shares of Quidel in a report on Wednesday, October 25th. Finally, Zacks Investment Research cut shares of Quidel from a “hold” rating to a “strong sell” rating in a report on Thursday, December 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $53.50.
In other Quidel news, SVP Werner Kroll sold 7,565 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $39.50, for a total transaction of $298,817.50. Following the completion of the sale, the senior vice president now directly owns 10,261 shares of the company’s stock, valued at $405,309.50. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jack W. Schuler sold 12,000 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $48.50, for a total transaction of $582,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 385,790 shares of company stock valued at $15,902,715. 22.00% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/01/quidel-qdel-earning-somewhat-positive-media-coverage-accern-reports.html.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.